A celebration of the inspirational figures behind innovation and achievement in pathology and laboratory medicine
12/29/2021 | Sponsored by Ultivue
Quickly customize your immune panels with Ultivue’s new innovation
03/09/2021 | Sponsored by Ultivue
Ultivue’s new multiplex immunofluorescence method optimizes standard anatomic pathology workflows and accelerates assay development
02/21/2023 | Sponsored by Ultivue
Immune therapy has emerged as the new frontier of cancer treatment.
05/31/2022 | Sponsored by Ultivue
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized.
10/07/2021 | Sponsored by Ultivue
The relevance to understand the entire tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells.
05/31/2021 | Sponsored by Ultivue
The relevance to understand the entire tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells...
08/02/2020 | Sponsored by Ultivue
Targeting of the programmed cell death protein (PD-1)/ programmed death-ligand 1 (PD-L1) axis with checkpoint inhibitors has changed clinical practice in non-small cell lung cancer (NSCLC).
06/18/2019 | Sponsored by Ultivue
This webinar will focus on user experiences using the Ultivue InSituPlex fluorescence multiplex IHC platform.
Register to access our FREE online portfolio, request the magazine in print and manage your preferences.
Register
Genetic Counseling
The Future Lies in Phenomic Medicine
Trusted Bodies for PGx